Over the last decades, a complex system has been identified with classical and regulatory pathways containing essential peptides and enzymes.7 Some of the RAS peptides, angiotensin II, have been associated with increased pro-inflammatory cytokines and decreased anti-inflammatory cytokines in Alzheimer’s disease.6 Angiotensin II also increases oxidative stress and neurovascular damage, and ATR1B in animal studies has been shown to counteract these effects.6 Thus, measuring these additional pathological markers would add valuable information. Here, AGT is linked to early-onset autosomal dominant Alzheimer disease.